Abstract
An incumbent biologic pharmaceutical manufacturer’s strategic entry-deterring decisions are examined in a two-player game. The Nash-equilibrium solutions show that the likelihood of the incumbent choosing deterrence investments rises with market size; but the optimal entry choice has a non-monotonic relationship with the size of the market. The paper also examines the optimal choices of the social planner seeking to foster competition through biosimilars entry and discourage entry-deterrence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
